Wyzga Michael S
SEC-identified person · CIK 1201256 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Tvardi Therapeutics, Inc. TVRD | Director | filed 2025–2026 |
| Mereo Biopharma Group plc MREO | Director | filed 2024–2026 |
| X4 Pharmaceuticals, Inc XFOR | Director | filed 2019–2026 |
| Invivyd, Inc. IVVD | Director | filed 2021–2023 |
| Logicbio Therapeutics, Inc. LOGC | Director | filed 2018–2022 |
| Exact Sciences Corp EXAS | Director | filed 2015–2021 |
| Oncomed Pharmaceuticals Inc OMED | Director | filed 2013–2018 |
| Akebia Therapeutics, Inc. AKBA | Director | filed 2014–2018 |
| Idenix Pharmaceuticals INC IDIX | Director | filed 2012–2014 |
| Radius Health, Inc. RDUS | Director · Chief Executive Officer | filed 2012–2012 |
| Genzyme Corp u4yfvwk$ | Executive VP and CFO | filed 2006–2011 |
| Altus Pharmaceuticals Inc. ALTU | Director | filed 2006–2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.